Balaprakash chosen for Tennessee’s new AI advisory council
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.
When Kashif Nawaz looks at a satellite map of the U.S., he sees millions of buildings that could hold a potential solution for the capture of carbon dioxide, a plentiful gas that can be harmful when excessive amounts are released into the atmosphere, raising the Earth’s temperature.
Nuclear physicist Caroline Nesaraja of the Department of Energy’s Oak Ridge National Laboratory evaluates nuclear data vital to applied and basic sciences.
Since the 1930s, scientists have been using particle accelerators to gain insights into the structure of matter and the laws of physics that govern our world.
As Hurricane Dorian raged through the Bahamas, researchers at Oak Ridge National Laboratory worked around the clock to aid recovery efforts for one of the Caribbean’s worst storms ever.
Marcel Demarteau is director of the Physics Division at the Department of Energy’s Oak Ridge National Laboratory. For topics from nuclear structure to astrophysics, he shapes ORNL’s physics research agenda.
The University of Texas at San Antonio (UTSA) has formally launched the Cybersecurity Manufacturing Innovation Institute (CyManII), a $111 million public-private partnership.
A multi-institutional team, led by a group of investigators at Oak Ridge National Laboratory, has been studying various SARS-CoV-2 protein targets, including the virus’s main protease. The feat has earned the team a finalist nomination for the Association of Computing Machinery, or ACM, Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research.
NellOne Therapeutics has licensed a drug delivery system from the Department of Energy’s Oak Ridge National Laboratory that is designed to transport therapeutics directly to cells infected by SARS-CoV-2, the virus causing COVID-19.
When Sandra Davern looks to the future, she sees individualized isotopes sent into the body with a specific target: cancer cells.